<DOC>
	<DOC>NCT02173574</DOC>
	<brief_summary>The purpose of Part 1 is to inform dose selection for use of alisporivir and EDP239 in combination and obtain initial safety data for co-administration of alisporivir and EDP239 to support future treatment studies in patients. The purpose of Part 2 is to inform the drug-drug interaction potential of EDP239 more broadly and possibly facilitate the interpretation of lower than expected alisporivir concentrations in Part 1, if observed.</brief_summary>
	<brief_title>Two-way Interaction Between Alisporivir and EDP239</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Male or female subjects 18 to 55 years of age Body weight at least 50 kg Women of child bearing potential Tobacco use History or evidence of any inherited bilirubin disease or disorder, including not not necessarily limited to DubinJohnson Syndrome, Gilbert's syndrome, and Rotor Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hepatitis C Virus, Viral, Antiviral, Infection, Infectious disease, alisporivir, EDP239, DEB025</keyword>
</DOC>